Lipid Metabolism Practice Questions

Q: What is the primary consequence of carnitine palmitoyltransferase I (CPT I) deficiency in fatty acid metabolism?

Decreased fatty acid oxidation. ***Decreased fatty acid oxidation*** - CPT I is crucial for transporting **long-chain fatty acids** into the mitochondrial matrix. A deficiency impairs this transport, preventing fatty acids from undergoing **beta-oxidation**. - Without proper entry into the mitochondria, fatty acids cannot be broken down to produce **acetyl-CoA** and energy, leading to a shortage of ATP derived from fat metabolism. - This represents the **primary functional defect** — the loss of the enzyme's physiological role in energy production. *Accumulation of fatty acyl-CoA* - While accumulation of fatty acyl-CoA in the cytoplasm does occur as a **direct biochemical consequence**, it represents the "what accumulates" rather than the "loss of function" that defines the primary metabolic impact. - In the context of enzyme deficiencies, the **primary consequence** refers to the loss of the catalytic function (decreased oxidation), while accumulation is a **downstream effect** of that functional loss. - Both occur simultaneously, but decreased oxidation is the pathophysiological hallmark of CPT I deficiency. *Increased gluconeogenesis* - CPT I deficiency actually leads to **decreased gluconeogenesis**, not increased, due to insufficient energy from fatty acid oxidation. - The lack of **acetyl-CoA** reduces the allosteric activation of pyruvate carboxylase, impairing glucose synthesis from non-carbohydrate sources. - Clinically presents as **hypoketotic hypoglycemia**, particularly during fasting states. *Increased production of ketone bodies* - Ketone body production relies on the **beta-oxidation of fatty acids** to produce acetyl-CoA, which is then used in the liver for ketogenesis. - In CPT I deficiency, the impaired fatty acid oxidation directly causes **reduced production of acetyl-CoA** and therefore **decreased ketone body synthesis**, leading to hypoketonemia. - The hypoketotic state distinguishes CPT I deficiency from other metabolic disorders.

Q: Which of the following hormones is synthesized from cholesterol and plays a crucial role in the stress response?

Cortisol. ***Cortisol*** - **Cortisol** is a **glucocorticoid** hormone synthesized from **cholesterol** in the adrenal cortex. - It plays a critical role in the body's **stress response** by increasing blood glucose, suppressing the immune system, and influencing metabolism. *Insulin* - **Insulin** is a peptide hormone, not a steroid, and is synthesized from **proinsulin** in the pancreatic beta cells. - Its primary role is to regulate **blood glucose levels** by facilitating glucose uptake into cells, not directly in the stress response in the same manner as cortisol. *Thyroxine* - **Thyroxine** (T4) is an **amine hormone** derived from the amino acid **tyrosine** and iodine, not cholesterol. - It primarily regulates **metabolism**, growth, and development, playing a more chronic, overarching role rather than an acute stress response. *Epinephrine* - **Epinephrine** (adrenaline) is a **catecholamine** hormone, derived from the amino acid **tyrosine**, not cholesterol. - While it is a key hormone in the "fight-or-flight" **stress response**, its synthesis pathway is different from steroid hormones.

Q: Which enzyme deficiency leads to the accumulation of glucocerebroside in macrophages, resulting in Gaucher disease?

β-glucosidase. ***β-glucosidase*** - This enzyme, also known as **glucocerebrosidase**, is deficient in **Gaucher disease**. - Its deficiency leads to the harmful accumulation of **glucocerebroside** within lysosomes, particularly within **macrophages**. *Hexosaminidase A* - Deficiency of **Hexosaminidase A** is characteristic of **Tay-Sachs disease**, leading to the accumulation of **GM2 gangliosides**. - Tay-Sachs typically presents with neurological degeneration, rather than macrophage accumulation of glucocerebroside. *Sphingomyelinase* - A deficiency in **sphingomyelinase** is the cause of **Niemann-Pick disease**, resulting in the accumulation of **sphingomyelin**. - Niemann-Pick disease affects various organs and is characterized by hepatosplenomegaly and neurological deterioration in severe forms. *α-galactosidase A* - **Fabry disease** is caused by a deficiency in **α-galactosidase A**, leading to the buildup of **globotriaosylceramide (Gb3)**. - Fabry disease primarily affects the heart, kidneys, and nervous system, and does not involve glucocerebroside accumulation.

Q: In patients with Retinitis pigmentosa, which of the following substances is known to have decreased levels?

Docosahexaenoic acid (DHA). ***Docosahexaenoic acid (DHA)*** - **Docosahexaenoic acid (DHA)** is a crucial **omega-3 fatty acid** abundantly found in the **photoreceptor cell membranes**, particularly in the retina. - Reduced levels of DHA are frequently observed in patients with **retinitis pigmentosa**, suggesting its role in disease pathogenesis and retinal health. *Arachidonic acid* - **Arachidonic acid** is an **omega-6 fatty acid** and a precursor to many signaling molecules, but its levels are **not typically decreased** in retinitis pigmentosa. - It plays a **pro-inflammatory role** and is involved in various physiological processes, distinct from the primary metabolic defects in retinitis pigmentosa. *Linoleic acid* - **Linoleic acid** is an essential **omega-6 fatty acid** and a precursor to arachidonic acid, but its deficiencies are not characteristic of retinitis pigmentosa. - It is crucial for **skin barrier function** and overall health, but its metabolic pathways are distinct from those primarily affected in retinal degenerations. *Thromboxane* - **Thromboxane** is a **lipid mediator** primarily involved in **platelet aggregation** and vasoconstriction. - It is not directly associated with the metabolic pathways or structural integrity of the retina, and its levels are not typically altered in retinitis pigmentosa.

Q: Which of the following conditions is characterized by a lack of genetically mediated VLDL overproduction?

Hypoapobetalipoproteinemia. ***Hypoapobetalipoproteinemia*** - This condition is characterized by **reduced production of apolipoprotein B**, leading to abnormally low levels of **VLDL and LDL** in the blood due to genetic mutations affecting apolipoprotein B synthesis or secretion. - Unlike the other options, it explicitly involves a *lack* of VLDL overproduction, making it the correct answer. *Familial combined hyperlipidemia* - This is a common genetic disorder characterized by **overproduction of VLDL** and occasionally decreased clearance of LDL, leading to elevated total cholesterol and triglycerides. - Patients often present with **elevated LDL and VLDL levels**, directly contradicting a lack of VLDL overproduction. *Familial dyslipidemic hypertension* - This condition is associated with a cluster of metabolic abnormalities, including **elevated triglycerides** (often secondary to VLDL overproduction) and hypertension. - The dyslipidemia component involves **increased VLDL production**, contributing to hypertriglyceridemia, rather than a lack of it. *LDL subclass B* - Refers to a predominance of **small, dense LDL particles**, which are more atherogenic than large, buoyant LDL particles. - The presence of small, dense LDL is often associated with conditions like **hypertriglyceridemia** and **insulin resistance**, which can be driven by increased VLDL production, not a lack thereof.

Q: What is the parameter that is used to assess lipid peroxidation?

Malondialdehyde. ***Malondialdehyde*** - **Malondialdehyde (MDA)** is a well-established and commonly used biomarker to quantify the level of **lipid peroxidation** in biological systems. - It is a **reactive aldehyde** formed during the decomposition of polyunsaturated fatty acids, particularly through **free radical attack**. *CRP* - **CRP (C-reactive protein)** is a general **inflammatory marker** that indicates acute phase responses in the body. - While inflammation can be associated with oxidative stress, CRP itself does not directly measure **lipid peroxidation**. *hsCRP* - **hsCRP (high-sensitivity C-reactive protein)** is a more sensitive measure of **inflammation**, often used to assess cardiovascular risk. - Like standard CRP, it is an **indicator of systemic inflammation** and not a direct measure of **lipid peroxidation**. *Carboxymethyl lysine* - **Carboxymethyl lysine (CML)** is an **advanced glycation end-product (AGE)**, formed by non-enzymatic reactions between sugars and proteins or lipids. - It is a marker of **glycation and oxidative stress**, but it does not specifically measure **lipid peroxidation**.

Q: Which of the following statements about the properties of VLDL and LDL is true?

LDL is formed from VLDL.. ***LDL is formed from VLDL.*** - **Very low-density lipoprotein (VLDL)** is secreted by the liver and transports **triglycerides** to peripheral tissues. As most of the triglycerides are removed by **lipoprotein lipase**, VLDL is converted into **intermediate-density lipoprotein (IDL)** and then further to **low-density lipoprotein (LDL)**. - This conversion primarily occurs in the bloodstream as VLDL loses its triglyceride content. - This statement is **unambiguously true** and represents the established metabolic pathway. *VLDL remnants are primarily taken up by the liver.* - While this statement has some truth, **VLDL remnants (IDL)** have **two major fates**: approximately **50% are taken up by the liver** via apoE-mediated endocytosis through the **LDL receptor** and **LRP**, while the remaining **50% are converted to LDL** by hepatic lipase. - The term "primarily" (meaning mostly or mainly) is thus **not entirely accurate** since both pathways are equally significant. - In contrast, **chylomicron remnants** are almost exclusively (>90%) taken up by the liver, making this statement more applicable to them. *LDL is formed in the liver.* - The liver primarily produces and secretes **VLDL**, not LDL directly. - LDL is a product of the **catabolism** of VLDL in the circulation, not formed de novo in the liver. *In electrophoresis, VLDL migrates less cathodal than LDL.* - In standard **agarose gel electrophoresis**, **VLDL** migrates in the **pre-beta** region, which is **more cathodal** (less anodic) than **LDL** which migrates in the **beta** region. - This means VLDL is more cathodal than LDL, making this statement **incorrect** (it states the opposite).

Q: Arachidonic acid oxidation involves how many cycles of beta oxidation?

9. ***Correct Answer: 9*** - **Arachidonic acid** is a 20-carbon fatty acid (C20:4). For a fatty acid with *n* carbons, the number of beta-oxidation cycles required is **(n/2) - 1**. - Therefore, for **arachidonic acid** (n=20), the number of beta-oxidation cycles is (20/2) - 1, which equals 10 - 1 = **9 cycles**. - Each cycle removes 2 carbons as acetyl-CoA, shortening the fatty acid chain progressively. *Incorrect Option: 10* - This number represents the total number of **acetyl-CoA** molecules generated from a 20-carbon fatty acid, not the number of beta-oxidation cycles. - Each beta-oxidation cycle produces one **acetyl-CoA** and reduces the fatty acid chain by two carbons; the last cycle yields two **acetyl-CoA** molecules directly. *Incorrect Option: 20* - This value corresponds to the total number of carbons in **arachidonic acid**, not the number of beta-oxidation cycles. - The number of beta-oxidation cycles is significantly less than the total carbon count. *Incorrect Option: 8* - This number would be correct for an 18-carbon fatty acid like **stearic acid** (18/2 - 1 = 8), not for **arachidonic acid**. - The calculation explicitly depends on the exact number of carbon atoms in the fatty acid chain.

Q: Which of the following is NOT a product derived from HMG CoA?

Bile pigments. ***Bile pigments*** - **Bile pigments** (like bilirubin and biliverdin) are derived from the degradation of **heme** from red blood cells and are completely unrelated to the HMG-CoA pathway. - Bile pigments are NOT products of cholesterol or isoprenoid metabolism. *Ubiquinone* - **Ubiquinone** (Coenzyme Q10) is synthesized via the **mevalonate pathway**, which begins with HMG-CoA being converted to mevalonate by **HMG-CoA reductase**. - The mevalonate pathway produces **isopentenyl pyrophosphate (IPP)**, which is used to synthesize ubiquinone, making it a downstream product of HMG-CoA. *Dolichol* - **Dolichol** is a long-chain isoprenoid alcohol essential for **N-glycosylation** of proteins in the endoplasmic reticulum. - Like ubiquinone, dolichol is synthesized from **isoprenoid units** derived from the mevalonate pathway, making it a product of HMG-CoA metabolism. *Ketone bodies* - **Ketone bodies** (acetoacetate and β-hydroxybutyrate) are directly synthesized from **HMG-CoA** in the mitochondria during fasting or low carbohydrate states. - The enzyme **HMG-CoA lyase** cleaves HMG-CoA to produce acetoacetate, which is then converted to other ketone bodies.

Question 1

What is the primary consequence of carnitine palmitoyltransferase I (CPT I) deficiency in fatty acid metabolism?

Accepted Answer

Decreased fatty acid oxidation

Answer

Increased gluconeogenesis

Answer

Accumulation of fatty acyl-CoA

Answer

Increased production of ketone bodies

Question 2

Which of the following hormones is synthesized from cholesterol and plays a crucial role in the stress response?

Accepted Answer

Cortisol

Answer

Insulin

Answer

Thyroxine

Answer

Epinephrine

Question 3

What is the role of carnitine in fatty acid oxidation?

Accepted Answer

Transports fatty acids into mitochondria, facilitating β-oxidation

Answer

Activates fatty acids by converting them to acyl-CoA

Answer

Regulates the rate of β-oxidation by controlling enzyme activity

Answer

Converts fatty acids into ketone bodies

Question 4

Which enzyme deficiency leads to the accumulation of glucocerebroside in macrophages, resulting in Gaucher disease?

Accepted Answer

β-glucosidase

Answer

Hexosaminidase A

Answer

Sphingomyelinase

Answer

α-galactosidase A

Question 5

In patients with Retinitis pigmentosa, which of the following substances is known to have decreased levels?

Accepted Answer

Docosahexaenoic acid (DHA)

Answer

Thromboxane

Answer

Arachidonic acid

Answer

Linoleic acid

Question 6

Which of the following conditions is characterized by a lack of genetically mediated VLDL overproduction?

Accepted Answer

Hypoapobetalipoproteinemia

Answer

Familial dyslipidemic hypertension

Answer

LDL subclass B

Answer

Familial combined hyperlipidemia

Question 7

What is the parameter that is used to assess lipid peroxidation?

Accepted Answer

Malondialdehyde

Answer

CRP

Answer

hsCRP

Answer

Carboxymethyl lysine

Question 8

Which of the following statements about the properties of VLDL and LDL is true?

Accepted Answer

LDL is formed from VLDL.

Answer

VLDL remnants are primarily taken up by the liver.

Answer

LDL is formed in the liver.

Answer

In electrophoresis, VLDL migrates less cathodal than LDL.

Question 9

Arachidonic acid oxidation involves how many cycles of beta oxidation?

Accepted Answer

9

Answer

20

Answer

8

Answer

10

Question 10

Which of the following is NOT a product derived from HMG CoA?

Accepted Answer

Bile pigments

Answer

Dolichol

Answer

Ketone bodies

Answer

Ubiquinone

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?